CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Citadel Technologies

Citadel Technologies is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tweed

Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.

Intendis Inc

Intendis Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oakwood Laboratories

Oakwood Laboratories is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccuMed

AccuMed Inc. is a Lawrence Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.